Case Studies on Changes and Proposed Process Development Approaches Reflecting Applicability of PDA Technical Report No. 89: Strategies for Vaccine Development and Lifecycle Management

References

1. 1.↵
   Parenteral Drug Association Inc. Technical Report No. 89: Strategies for Vaccine Development and Lifecycle Management; PDA: Rockville, MD, 2023.
2. 2.↵
   BioPhorum Approach to the Registration of Innovative Raw Materials Using Quality by Design (QbD) Principles, 2022. https://www.biophorum.com/download/biophorum-approach-to-the-registration-of-innovative-raw-materials-using-quality-by-design-principles/ (accessed May 15, 2024).
3. 3.↵
   1. McGoldrick M.,
   2. Gastineau T.,
   3. Wilkinson D.,
   4. Campa C.,
   5. De Clercq N. D.,
   6. Mallia-Milanes A.,
   7. Germay O.,
   8. Krishnan J.,
   9. Van Ooij M.,
   10. Thien M. P.,
   11. Mlynarczyk P. J.,
   12. Saltus E.,
   13. Juvin P.,
   14. Clenet D.,
   15. Basso A.,
   16. Dellepiane N.,
   17. Pagliusi S.,
   18. Collaço de Moraes Stávale M.,
   19. Sivaramakrishnan V. H.,
   20. Desai S.

   How to Accelerate the Supply of Vaccines to All Populations Worldwide? Part I: Initial Industry Lessons Learned and Practical Overarching Proposals Leveraging the COVID-19 Situation. Vaccine 2022, 40 (9), 1215–1222.

   OpenUrlPubMed
4. 4.↵
   1. McGoldrick M.,
   2. Gastineau T.,
   3. Wilkinson D.,
   4. Campa C.,
   5. De Clercq N.,
   6. Mallia-Milanes A.,
   7. Germay O.,
   8. Krishnan J.,
   9. Van Ooij M.,
   10. Thien M. P.,
   11. Mlynarczyk P. J.,
   12. Saltus E.,
   13. Wauters F.,
   14. Juvin P.,
   15. Clenet D.,
   16. Basso A.,
   17. Dellepiane N.,
   18. Pagliusi S.,
   19. Collaço de Moraes Stávale M.,
   20. Sivaramakrishnan V. H.,
   21. Desai S.

   How to Accelerate the Supply of Vaccines to All Populations Worldwide? Part II: Initial Industry Lessons Learned and Detailed Technical Reflections Leveraging the COVID-19 Situation. Vaccine 2022, 40 (9), 1223–1230.

   OpenUrlPubMed
5. 5.↵
   U.S. Food and Drug Administration. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products, 2011. https://www.fda.gov/media/79856/download.
6. 6.↵
   World Health Organization, Biologicals Unit. Manual of Laboratory Methods for Potency Testing of Vaccines Used in the WHO Expanded Programme on Immunization, 1995. https://apps.who.int/iris/handle/10665/58651 (accessed November 16, 2023).
7. 7.↵
   1. Hendriksen C. F. M.

   Humane Endpoints in Vaccine Potency Testing. Procedia Vaccinol. 2011, 5, 221–226.

   OpenUrl
8. 8.
   1. Roduit B.,
   2. Hartmann M.,
   3. Folly P.,
   4. Sarbach A.,
   5. Baltensperger R.

   Prediction of Thermal Stability of Materials by Modified Kinetic and Model Selection Approaches Based on Limited Amount of Experimental Points. Thermochim. Acta 2014, 579, 31–39.

   OpenUrl
9. 9.↵
   1. Clénet D.

   Accurate Prediction of Vaccine Stability Under Real Storage Conditions and During Temperature Excursions. Eur. J. Pharm. Biopharm. 2018, 125, 76–84.

   OpenUrlPubMed
10. 10.↵
    1. Neyra C.,
    2. Clénet D.,
    3. Bright M.,
    4. Kensinger R.,
    5. Hauser S.

    Predictive Modeling for Assessing the Long-Term Thermal Stability of a New Fully-Liquid Quadrivalent Meningococcal Tetanus Toxoid Conjugated Vaccine. Int. J. Pharm. 2021, 609, 121143.

    OpenUrlPubMed
11. 11.↵
    1. Campa C.,
    2. Pronce T.,
    3. Paludi M.,
    4. Weusten J.,
    5. Conway L.,
    6. Savery J.,
    7. Richards C.,
    8. Clénet D.

    Use of Stability Modeling to Support Accelerated Vaccine Development and Supply. Vaccines 2021, 9 (10), 1114.

    OpenUrlPubMed
12. 12.↵
    1. Huelsmeyer M.,
    2. Kuzman D.,
    3. Bončina M.,
    4. Martinez J.,
    5. Steinbrugger C.,
    6. Weusten J.,
    7. Calero-Rubio C.,
    8. Roche W.,
    9. Niederhaus B.,
    10. VanHaelst Y.,
    11. Hrynyk M.,
    12. Ballesta P.,
    13. Achard H.,
    14. Augusto S.,
    15. Guillois M.,
    16. Pszczolinski C.,
    17. Gerasimov M.,
    18. Neyra C.,
    19. Ponduri D.,
    20. Ramesh S.,
    21. Clénet D.

    A Universal Tool for Stability Predictions of Biotherapeutics, Vaccines and In Vitro Diagnostic Products. Sci. Rep. 2023, 13 (1), 10077.

    OpenUrlPubMed
13. 13.↵
    1. Roduit B.,
    2. Luyet C. A.,
    3. Hartmann M.,
    4. Folly P.,
    5. Sarbach A.,
    6. Dejeaifve A.,
    7. Dobson R.,
    8. Schroeter N.,
    9. Vorlet O.,
    10. Dabros M.,
    11. Baltensperger R.

    Continuous Monitoring of Shelf Lives of Materials by Application of Data Loggers with Implemented Kinetic Parameters. Molecules 2019, 24 (12), 2217.

    OpenUrlPubMed
14. 14.↵
    1. Clénet D.,
    2. Hourquet V.,
    3. Woinet B.,
    4. Ponceblanc H.,
    5. Vangelisti M.

    A Spray Freeze Dried Micropellet Based Formulation Proof-of-Concept for a Yellow Fever Vaccine Candidate. Eur. J. Pharm. Biopharm. 2019, 142, 334–343.

    OpenUrlPubMed
15. 15.↵
    CEPI; Gavi; World Health Organization. Best Practices for Determining and Updating Storage Temperature and Shelf-Life Workshop. Presented at COVAX Workshop, December 9, 2020. https://media.tghn.org/medialibrary/2020/12/20201209_COVAX_Storage_temperature_and_shelf_life_workshop_presentation.pdf (accessed May 15, 2024)